James P. Jewell

Idaho National Laboratory — United States

Medicine · Health Sciences

15h-index1.8kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(16), Cannabis and Cannabinoid Research(10), Neurotransmitter Receptor Influence on Behavior(6), PI3K/AKT/mTOR signaling in cancer(4), Neuroscience and Neuropharmacology Research(3)

Publications39 total

Advanced Moderator Material Handbook (FY23 Version)
2023· 4 citedOpen Access
Supplementary Methods, Table 1, Figure Legends 1-5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 3 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Methods, Table 1, Figure Legends 1-5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 2 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 1 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 3 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 4 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Data from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 4 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 2 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Data from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 1 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
An orally available non-nucleotide STING agonist with antitumor activity
Science·2020· 611 cited
Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING
ACS Medicinal Chemistry Letters·2018· 163 citedOpen Access
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors
Bioorganic & Medicinal Chemistry Letters·2016· 17 citedOpen Access
MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation
Bioorganic & Medicinal Chemistry Letters·2016· 4 citedOpen Access
Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors
Journal of Medicinal Chemistry·2015· 27 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Bo‐Sheng Pan(18), Jason D. Katz(18), Alexander A. Szewczak(18), Harold Hatch(17), Ilona Kariv(16), Lenora J. Davis(16), Sujal V. Deshmukh(16), Gaozhen Hang(16), Kaiko Kunii(16), Bart Lutterbach(16), Xianlu Qu(16), John F. Reilly(16), Qinwen Zeng(16), Christopher J. Dinsmore(16), Linus S. Lin(15), Grace K.Y. Chan(15), Mélissa Chénard(15), An Chi(15), W. Wayt Gibbs(15), Cloud P. Paweletz(15)